Recent advances in single-cell transcriptomics are ideally placed to unravel intratumoral heterogeneity and selective resistance of cancer stem cell (SC) subpopulations to molecularly targeted cancer therapies. However, current single-cell RNA-sequencing approaches lack the sensitivity required to reliably detect somatic mutations. We developed a method that combines highsensitivity mutation detection with whole-transcriptome analysis of the same single cell. We applied this technique to analyze more than 2,000 SCs from patients with chronic myeloid leukemia (CML) throughout the disease course, revealing heterogeneity of CML-SCs, including the identification of a subgroup of CML-SCs with a distinct molecular signature that selectively persisted during prolonged therapy. Analysis of nonleukemic SCs from patients with CML also provided new insights into cell-extrinsic disruption of hematopoiesis in CML associated with clinical outcome. Furthermore, we used this single-cell approach to identify a blast-crisis-specific SC population, which was also present in a subclone of CML-SCs during the chronic phase in a patient who subsequently developed blast crisis. This approach, which might be broadly applied to any malignancy, illustrates how single-cell analysis can identify subpopulations of therapy-resistant SCs that are not apparent through cell-population analysis.
Molecularly targeted therapies for cancer frequently induce impressive remissions; however, complete disease elimination remains rare, and patients remain at risk of disease relapse. At a cellular level, this is likely to reflect intratumoral heterogeneity, with differential response to treatment in distinct tumor subpopulations 1 . This phenomenon relates to the proposed hierarchical organization of some tumors, in which only rare cancer stem cells (CSCs) are capable of tumor propagation [2] [3] [4] . There is now ample evidence for the existence of such rare CSCs in some tumors, subsets of which are resistant to therapy and persist during remission [2] [3] [4] . However, studies characterizing CSCs during remission are lacking, which reflects in part the fact that these residual CSCs are typically rare and outnumbered by their normal tissue counterparts, from which they cannot easily be separated 5, 6 .
Advances in single-cell gene-expression techniques offer great potential for studying the CSC heterogeneity that might underlie therapy resistance 1, [7] [8] [9] . Thus far, however, the application of single-cell RNA sequencing in cancer has been relatively limited in patients who achieve remission after therapy 1, [7] [8] [9] [10] [11] [12] , partly because the detection of somatic mutations is grossly underappreciated using current techniques 11 .
This primarily relates to poor coverage in the RNA-sequencing reads from single cells across the specific mutated region of a gene, owing to both technical dropouts and stochastic gene expression in individual cells 8 . Thus, it is difficult to simultaneously apply single-cell transcriptome analysis with highly sensitive detection of specific mutations; the latter is essential for reliably distinguishing normal cells from somatically mutated cells that form part of the malignant clone. This is of particular importance when analyzing CSC during remission, at which point malignant cells are rare and may largely share transcriptomic features with normal tissue counterparts.
CML is a paradigm for molecularly targeted therapy and an ideal disease in which to explore the cellular basis of selective resistance to targeted therapy 13, 14 . CML is less genetically complex than most cancers and is defined by the presence of the BCR-ABL fusion gene, the product of which is the target of tyrosine kinase inhibitor (TKI) treatments, which have improved outcomes dramatically for this disease 15 . However, chronic-phase CML (CP-CML) is propagated by rare CML-SCs that are selectively resistant to TKI therapy and incompletely eradicated in most patients 16, 17 , which leads to frequent relapse following treatment discontinuation 18 . CML-SCs reside in the same phenotypic compartment as their normal hematopoietic stem cell (HSC) counterparts, and both express a CD34 + CD38 -surface phenotype 5, 6 . Techniques for selectively analyzing BCR-ABL + SCs throughout the disease course are not currently available. It therefore remains to be established whether therapy-resistant CML-SCs following TKI therapy represent the stochastic persistence of heterogeneous CML-SCs; a selective persistence of a pre-existing distinct, therapyresistant CML-SC subset; or a resistant CML-SC with novel properties that evolved as a result of the therapeutic selection process.
In addition, there is ample evidence in hematological malignancies that dysregulated hematopoiesis occurs as much through extrinsic disruption of the normal-HSC compartment as through intrinsic expansion of the leukemic clones [19] [20] [21] . For example, recent evidence from mouse models supports the involvement of nonclonal BCR-ABL − SCs in the CML disease phenotype 22, 23 . However, in the absence of single-cell analysis enabling the separation of BCR-ABL − and BCR-ABL + SCs within individual patients, it remains unclear to what degree the disruption of BCR-ABL − SCs occurs in patients with CML, and how disruption of the nonclonal SC compartment might correlate with response to treatment.
Herein, we developed a new protocol that integrates fluorescenceactivated cell sorting (FACS), high-sensitivity single-cell mutation detection and single-cell RNA sequencing. We apply this method to characterize distinct molecular signatures of SC subpopulations in human CML samples from diagnosis through remission and disease progression.
RESULTS

Combined single-cell mutation detection and transcriptomics
Presence of the BCR-ABL fusion gene remains the only unequivocal marker of CML-SCs, and we therefore first sought to determine the sensitivity of BCR-ABL detection using Smart-seq2, a commonly used single-cell RNA-sequencing approach 8, 24, 25 , by analyzing the BCR-ABL + K562 human erythroleukemic cell line derived from a patient in blast crisis of CML 26 . BCR-ABL transcripts were not detected in as many as 18 of 24 cells (75%; Fig. 1a) , despite the generation of satisfactory complementary DNA (cDNA) libraries, as determined through bioanalyser analysis of the size and concentration of amplified cDNA libraries (Supplementary Fig. 1a ). We obtained a similar result using a commercial nanofluidic platform 27 ( Supplementary  Fig. 1b ) and across a range of other myeloid leukemia mutation hot spots ( Supplementary Fig. 1c ), which enabled us to validate that current single-cell RNA-sequencing techniques do not enable sensitive mutation detection 10 .
To improve the sensitivity of BCR-ABL detection, we developed a BCR-ABL-targeted Smart-seq2 protocol (BCR-ABL tSS2). By multiplexing BCR-ABL-specific primers at the reverse transcription and amplification steps, BCR-ABL detection was improved to 100% of K562 cells in plate-based (Fig. 1b) or microfluidic-based platforms ( Supplementary Figs. 1d and 2a-d) . Importantly, there was no evidence of bias caused by BCR-ABL tSS2 in relation to library quality ( Supplementary Fig. 2d ), and good correlation existed between the level of expression of 14,240 RefSeq genes (Fig. 1c ) generated by Smart-seq2 or BCR-ABL tSS2; these samples also did not show separate clustering ( Fig. 1d and Supplementary Fig. 3 ). BCR-ABL plasmid 'spike-in' experiments demonstrated detection sensitivity to single molecules of BCR-ABL, with expected Poisson distribution. Importantly, no BCR-ABL amplification was observed from any negative control cells in this case (Fig. 1e) or in any subsequent experiment (n = 232 cells). This BCR-ABL tSS2 method therefore allows for highly specific, sensitive and quantitative BCR-ABL detection with parallel unbiased whole-transcriptome analysis from the same single cell.
Single-cell RNA sequencing and BCR-ABL detection in CML stem cells Because human HSCs are small and highly quiescent as compared to K562 cells, we first analyzed 232 Lin -CD34 + CD38 -BM cells from five healthy human donors (normal HSCs) using BCR-ABL tSS2. Satisfactory cDNA libraries were generated (Supplementary Fig. 4a) , with a plateau in the numbers of genes detected above 1 × 10 6 mapped reads/cell (Fig. 2a) . With an average sequencing depth of 3.4 × 10 6 mapped reads, a mean of 3,445 genes was detected in each cell (Supplementary Fig. 4b) . 12,018 genes were detected (RPKM ≥1) in single-cell ensembles (sequencing data from all 232 cells were pooled in silico), which correlated well with cell-population data ( Supplementary Fig. 4c ) providing sufficient sensitivity to detect low-level expressed transcripts (Supplementary Fig. 4d ), in line with previous reports 28 . Human HSCs clustered separately and were more X axis indicates the absolute number of copies of BCR-ABL expected to be present in each reaction, calculated using a commercial standard. Table at top shows the numbers of wells that would be expected to contain at least one copy of BCR-ABL by Poisson distribution and the actual frequency of amplification following BCR-ABL tSS2. VOLUME 23 | NUMBER 6 | JUNE 2017 nAture medicine SOD2  CTSW  IFITM1  H2AFY  PDE6D  GOLGABB  GOLGABA  CSF3R  NCKAP1L  PREX2  CYB5R1  PTTG1IP  FREM1  GAS2  ZBTB20  LOC101928834  SH2D3C  TIGD1  GOLGABS  GOLGABT  FCER1A  TMEM163  TESPA1  PTRF  IFT57  LINC00539  EPS15  LOC101927221  CCDC115  LLPH  TMEM248  STON2  RAVER2  ANKRD27  COPS7A  WDR77  PYCR1  ADAM10  PHF3  DUXAP10  MYCT1  DDX6  PTPRCAP  FTH1P3  COX5A  FRG1  ADPGK  EMP3  ZDHHC6  CECR1  POLD3  APIP  LINC01515  CHEK1  ZC3HC1  FAM118A  COMMD1  SAT1  TACC1  DKFZP586I1420  DHPS  ALG13  RG52  PTPRE  AMICA1  PDE4B  CKLF  CXCR4  HHEX  CD53  MZB1  CALCOCO2  NSRP1 BCR-ABL heterogeneous than K562 cells (Fig. 2b and Supplementary Fig. 4e) . Importantly, independently processed cells from five different donors clustered together, illustrating stability of the data across independent experiments (Fig. 2b) .
We next analyzed 40 Lin -CD34 + CD38 -SCs from a patient with CML who was in hematologic remission following 3 months of TKI therapy (OX1407; Supplementary Table 1) . BCR-ABL was detected in 17/40 cells (43%) by BCR-ABL tSS2 and in 7/20 cells (35%; P = 0.8) by single-cell fluorescence in situ hybridization. We detected 12,499 genes in data ensembles, which correlated well with bulk-analysis data (Fig. 2c) . Comparison of BCR-ABL + and BCR-ABL − SCs identified genes showing differential expression (Fig. 2d,e) . The level of expression correlated well between single-cell RNA sequencing and qPCR data ( Fig. 2f-h; Supplementary Fig. 5a-c) . Taken together, these data provide proof of principle that BCR-ABL tSS2 can be applied to detect distinct gene expression in BCR-ABL + as compared to BCR-ABL − SCs from the same patient during TKI treatment.
Single-cell RNA sequencing of CML-SCs at diagnosis We next used BCR-ABL tSS2 to process 2,070 Lin -CD34 + CD38 -BM SCs from diagnosis samples from 20 patients with CP-CML (Supplementary Table 1 ). Two patients with CP-CML developed early progression to blast crisis (BC), and these cells were removed from the current analysis and analyzed in later experiments. As previously reported 29 , although the progenitor compartment was disrupted in patients with CML, the HSC-containing Lin -CD34 + CD38 -compartment was relatively intact phenotypically (Supplementary Fig. 6 ). As expected 5, 6, 30 , the frequency of BCR-ABL + SCs was variable (median: 69%, 9-94%; Supplementary Table 1) .
We selected 854 CP-CML-SCs (477 BCR-ABL + and 377 BCR-ABL − ) for sequencing and detected a mean of 3,591 genes/cell ( Supplementary  Fig. 7a ). Read depth and mapped reads/cell were not different between normal HSCs (n = 232), BCR-ABL − SCs and BCR-ABL + SCs (Supplementary Fig. 7b,c) . The expression of housekeeping genes, for example, B2M, was also comparable in the three groups ( Supplementary  Fig. 7d ). By contrast, whereas the mean number of genes detected was comparable between normal HSCs (n = 3,445) and BCR-ABL − SCs (n = 3,409), a significantly higher number of genes was detected in BCR-ABL + SCs (n = 3,735, P = 1.67 × 10 −6 , Supplementary Fig. 7e ). This correlated with BCR-ABL-driven proliferation; markedly increased proliferation gene expression (Fig. 3a) and reduced quiescence-associated gene expression (Fig. 3b) were observed in BCR-ABL + SCs in comparison with normal HSCs. By contrast, BCR-ABL − SCs showed similar proliferation (Supplementary Fig. 7f ) and quiescence-associated gene expression (Supplementary Fig. 7g ) as normal HSCs. Consequently, coexpression of G2M-associated genes was selectively increased in BCR-ABL + SCs (Supplementary Fig. 7h) .
t-distributed stochastic neighbor embedding (tSNE) analysis using 8,589 highly variable genes revealed distinct clustering of normal HSCs, BCR-ABL + and BCR-ABL − SCs (Fig. 3c) . Differentially expressed genes between normal HSCs and BCR-ABL + and BCR-ABL − SCs included many that had previously been implicated in CML pathogenesis ( Supplementary Fig. 8a and Supplementary Table 2 ), but also a number of novel candidate genes of interest, such as RXFP1, receptor for the hormone relaxin; the small GTPase RAB31; the spliceosome gene SRSF2; and the beta-galactoside-binding protein LGALS1 (Supplementary Fig. 8b and Supplementary Table 2 ). In silico generation of cell-ensemble data demonstrated that few of these differentially expressed genes would have been revealed without single-cell analysis (Supplementary Fig. 8c ).
Using the top 245 differentially expressed genes, BCR-ABL + cells clustered separately from BCR-ABL − SCs, importantly, without evidence of major patient-specific clustering (Fig. 3d) , which shows consistency of aberrant gene expression in BCR-ABL + SCs across different patients ( Supplementary Fig. 9a,b) .
Our comparison of BCR-ABL + SCs with normal HSCs and/or BCR-ABL − SCs showed expected enrichment in BCR-ABL + SCs for the large majority of established CML stem and progenitor gene sets (Supplementary Tables 3 and 4 and Supplementary Fig. 10 ). Analysis using unbiased gene sets (Supplementary Table 5 and Fig. 3e ) uncovered multiple gene sets selectively enriched in BCR-ABL + SCs (for example, overexpression of MTOR, E2F targets, G2M checkpoint, oxidative phosphorylation and glycolysis-associated gene expression; Supplementary Table 5 and Fig. 3e ), none of which showed enrichment through in silico bulk analysis of the same data set.
Importantly, our single-cell approach also uniquely allowed for analysis of BCR-ABL − SCs within the same patients-of relevance for recent evidence suggesting that the microenvironment is disrupted in mouse models of CML 22, 23 . Interleukin (IL)-6-associated gene expression and downstream mediators such as STAT5 were indeed significantly enriched in BCR-ABL − SCs in comparison with normal HSCs (Fig. 3e, Supplementary Fig. 10 and Supplementary Tables 4 and 5). Furthermore, other inflammation-associated gene expression, including those involved in the transforming growth factor (TGF)-β and tumor-necrosis factor (TNF)-α pathways, were also markedly enriched in BCR-ABL − SCs in comparison with normal HSCs (Fig. 3e) . Inflammation is an important suppressor of HSC function 31, 32 , including TGF-β and TNF-α, both of which are notably cell-extrinsic suppressors of HSCs 33, 34 .
Single-cell RNA sequencing of CML-SCs predicts TKI response Next, to establish the potential clinical utility of CML-SC singlecell gene expression signatures, in line with current guidelines 35 , we stratified patients with sufficient response data available as good (n = 11) or poor (n = 5) responders on the basis of subsequent achievement of a major molecular response (MMR) to TKI, defined as a BCR-ABL transcript level of <0.1% (Supplementary Table 1 ). There was no significant difference in the frequency of BCR-ABL + SCs between good (61%) and poor (58%) responders (P = 0.7). Although BCR-ABL + SCs at diagnosis did not clearly cluster according to response category (Fig. 4a) , BCR-ABL − SCs from poor-responder patients showed highly distinct clustering according to analysis of 5,611 highly variable genes (Fig. 4b) . Notably, in all five patients with CML who failed to achieve MMR, the frequency of BCR-ABL − SCs contained within the poor-responder cluster was higher than for all 11 patients who achieved MMR, in four cases with virtually all BCR-ABL − SCs falling within the poor-responder cluster (Fig. 4c) . The five patients with >10% of BCR-ABL − SCs falling within the poorresponder cluster had a markedly inferior likelihood of achieving MMR ( Fig. 4d ; P < 0.01).
Gene-set enrichment analysis (GSEA) also showed enrichment at diagnosis of gene expression associated with signaling pathways, inflammation, TGF-β and TNF-α in BCR-ABL − SCs from poor as compared to good responders ( Fig. 4e and Supplementary Table 6 ). By contrast, both BCR-ABL − and BCR-ABL + SCs from good responders showed enrichment of MYC, E2F and G2M-checkpoint gene expression, all of which are associated with increased proliferation ( Fig. 4e and Supplementary Table 6 ). These data demonstrate that BCR-ABL + , as well as BCR-ABL − SCs, in poor-responding patients are already at diagnosis expressing more quiescence-associated genes than in patients who will later achieve MMR; given that this was observed for both BCR-ABL + and BCR-ABL − SCs, this may reflect differences in cell-extrinsic, microenvironmental factors in good as compared to poor responders.
Given that poor responders showed upregulation of TGF-β-and TNF-α-pathway-associated gene expression, combined with a highly quiescent CML-SC signature, we reasoned that TGF-β and TNF-α might promote quiescence in the CML-SC compartment and thereby confer CML15  CML22  CML25  CML655  CML656  CML691  CML940  CML960  OX1249  OX1302  OX1674  OX2038  OX2286  OX664  OX710  OX714  OX824 TKI resistance. We therefore cultured single normal HSCs and CML-SCs in vitro, with or without TGF-β or TNF-α, and tracked the time it took for the SCs to divide. TNF-α promoted quiescence of both CML-SCs and normal HSCs (Supplementary Fig. 11 ). Notably, TGF-β more strongly influenced the rate of cell division of CML-SCs than that of normal HSCs (Supplementary Fig. 11 ). Taken together, these data highlight the power of single-cell (unlike bulk) RNA sequencing of CML-SCs at diagnosis to reveal gene-expression patterns in leukemic as well as nonleukemic SCs within the same patient.
Characterization of quiescent CML-SCs persisting during TKI therapy
We next analyzed 19 patients who had already commenced TKI therapy and had achieved at least hematological remission (normalization of blood counts), and most of whom showed additional cytogenetic response (Supplementary Table 1 ). In 11 of these patients, paired diagnosis and follow-up BM samples were available following either 3 or 6 months of TKI (Supplementary Table 1 ). In follow-up samples, the percentage of BCR-ABL + SCs (median: 9%, 0-82%) was lower than in diagnosis samples from the same patient (P = 0.0001; Supplementary Table 1) . From a total of 3,306 cells processed, we selected 245 BCR-ABL + SCs and 420 BCR-ABL − SCs for singlecell sequencing. Notably, unlike in diagnosis samples, the average number of genes detected in each cell was similar between BCR-ABL + (n = 3,284) and BCR-ABL − SCs (n = 3,196) in follow-up samples. Using the top 500 genes (as indicated by random forests analysis) informative for distinguishing normal HSCs from BCR-ABL + SCs at diagnosis and during remission (Supplementary Table 7) , tSNE analysis revealed two distinct clusters of remission BCR-ABL + SCs (group A and group B; Fig. 5a ). Group-A remission BCR-ABL + SCs were enriched for quiescence and HSC-associated gene expression, whereas group B showed enrichment of MYC, E2F and proliferation-associated gene sets (Fig. 5b and Supplementary Table 8) . Group-A cells were progressively enriched with more prolonged TKI treatment, accounting for 43% of BCR-ABL + SCs at 3 months and 84% at ≥1 year (P < 0.01; Fig. 5c ). This enrichment for group-A cells was even more striking when we included only patients who subsequently achieved MMR, with 65% and 91% of BCR-ABL + SCs falling in group A at 3 months and 1 year following the initiation of TKI treatment, respectively (P < 0.01; Fig. 5d; Supplementary Fig. 12a ). The only exceptions were one patient who temporarily interrupted TKI therapy and one patient who failed to achieve therapeutic imatinib levels, both of whom showed predominantly group-B SCs at 3 months ( Supplementary  Fig. 12b ). This supports the concept that an excess of group-B cells during TKI therapy identifies patients with inadequate BCR-ABL inhibition. We also noted that in 15 of 18 (83%) diagnosis samples, a minority of BCR-ABL + SCs clustered in group A (26% of all diagnosis BCR-ABL + SCs; Fig. 5a,c,d and Supplementary Fig. 12 ), although the frequency of group-A cells at diagnosis did not correlate with response to TKI in this small cohort of patients. Taken together, these data suggest that prolonged TKI treatment results in the selective persistence of a distinct and highly quiescent BCR-ABL + CML-SC subset (group A) already present at diagnosis, rather than a stochastic persistence of heterogeneous CML-SCs or a resistant CML-SC with novel properties. To better understand the selective persistence of quiescent CML-SCs during long-term TKI treatment, we therefore focused subsequent analysis on remission group-A cells.
Most group-A BCR-ABL + SCs clustered separately from normal HSCs (Fig. 5a) ; we detected 1,086 differentially expressed genes in group-A remission BCR-ABL + SCs in comparison with normal HSCs (Supplementary Table 9 ). We also detected 1,681 and 1,348 differentially expressed genes in group-A remission BCR-ABL + SCs in comparison with group-B remission BCR-ABL + SCs and BCR-ABL + SCs at diagnosis, respectively (Supplementary Table 9 ). In comparison with normal HSCs, group-A BCR-ABL + SCs showed enrichment of TGF-β-, TNF-α-(via nuclear factor (NF)-κB) and IL-6-JAK-STATassociated gene expression, whereas E2F-, G2M-checkpoint-and MYCassociated gene expression were enriched in normal HSCs (Fig. 5e,  Supplementary Fig. 13 and Supplementary Table 10) . Similar findings were obtained by comparing group-A remission cells with BCR-ABL − SCs during TKI treatment (Supplementary Fig. 13 ). These findings support the concept that group-A remission CML-SCs, characterized by marked quiescence-associated gene expression, selectively evade eradication by TKI. These cells show more quiescence-associated gene expression than normal HSCs or BCR-ABL − SCs during remission, likely because the latter are intrinsically much less sensitive to TKIs owing to an absence of BCR-ABL expression. TGF-β-and TNF-α (via NF-κB)-associated explore the possibility that single-cell sequencing of BCR-ABL + CMLSCs could already in CP predict a subsequent BC transformation. At the time of BC, tSNE analysis of CML-SCs revealed a separate cluster of BCR-ABL + SCs, clearly distinct from both normal HSCs, BCR-ABL + SCs from 18 patients with CP-CML at diagnosis and K562 cells (Fig. 6a) . Notably, myeloid and lymphoid BC BCR-ABL + SCs clustered together. Comparison of gene expression of the BC and CP BCR-ABL + SC clusters revealed 1,166 differentially expressed genes ( Fig. 6b and Supplementary Table 11 ), including overexpression of HGF 36 and reduced expression of the Wnt pathway negativeregulator EAF2 (ref. 37) .
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Two of the patients who developed BC following TKI initiation also had samples available from diagnosis, when the patients presented in CP (pre-BC) 12 months and 3 months before transformation to myeloid and lymphoid BC, respectively (Supplementary Table 1 ). All pre-BC cells from the patient transforming to myeloid BC 12 months later clustered with other CP-CML SCs (CP-CML cluster, gene expression was progressively more enriched within remission group-A BCR-ABL + SCs during the course of TKI treatment (Fig. 5f) , which supports that these pathways may be important to sustain of this resistant and quiescent CML-SC population during TKI treatment. Remission group-A BCR-ABL + SCs, also showed overexpression of Wnt/β-catenin-pathway-associated genes (GAS2 and CTNNB1), the TGF-β-pathway gene SKIL, regulators of NF-κB (NFKB1A and SQSTM (also known as p62)), the hypoxia factors HIF1A and the Wilms tumor protein (WT1) partner WTAP, as well as downregulation of the chemokine receptor CXCR4 and the transcription factor FOS, in comparison with normal HSCs (Fig. 5g and Supplementary Table 9 ). This single-cell analysis provides insight into pathways that may be involved in promoting the selective persistence of distinct BCR-ABL + SCs following TKI treatment.
Analysis of CML-SC heterogeneity during blast crisis
We next analyzed three patients with lymphoid (n = 2) or myeloid (n = 1) BC transformation of CML (Supplementary Table 1) , to IGJ  DNTT  FBXW7  EDEM1  LPAR6  CD79B  SERINC5  DHRS3  VPREB1  BLNK  TSPAN7  IL2RA   Cell  BANK1  EBF1  FAIM3  LTB  BLNK  CD19  CD79A  DNTT  IGJ  IRF8  LEF1  LY86  RAG1  VPREB1  VPREB3  CD33  CEBPA  CSF1R  ID2  IL3RA  IL6R  LY6E  MCL1  MPO  MSR1   P2RY14  MAN1A1  HGF  CHN1  MSR1  ST18  ISG20  S100A16  SMAD1  HLA-DRA  SOCS2  EAF2  NGFRAP1  SPINK2  GAS2  CPNE8  BEX4  BEX2  PRKACB  LAPTM4B  WBP5  ALDH1A1  PRSS57  KIAA0125  MEIS1  ICAM3  GOLGA8A Supplementary Fig. 14a) . However, the pre-BC SCs from the patient who, 3 months later, developed lymphoid BC fell into two distinct groups, one clustering close to the BC-SCs (BC cluster, n = 124), but notably with a minority (n = 8) clustering separately from the BC cluster within the CP-CML cluster (Fig. 6c) . This provides direct evidence of evolution from CP to BC within the SC compartment of this patient, before any clinical or morphological evidence of development of BC. In further support of this, the pre-BC single BCR-ABL + SCs cells falling within the BC cluster showed aberrant coexpression of myeloid and lymphoid genes in comparison with normal HSCs or CP-CMLSCs, as did cells within the BC cluster from all three of the investigated BC patients, whereas none of the pre-BC BCR-ABL + SCs cells clustering with the CP CML -SCs showed this aberrant coexpression pattern (Fig. 6d) , with validation of a number of aberrantly expressed genes by single-cell qPCR (Supplementary Fig. 14b) . Moreover, index-sorting analysis (allowing specific FACS data of individual cells to be linked with gene expression data from the same cell) of the rare pre-BC cells in the CP-SC cluster showed that they all resided within the normal Lin -CD34 + CD38 -CD90 + CD45RA -HSC compartment, whereas 62 of 68 of the pre-BC SCs falling in the BC-SC cluster had a distinct Lin -CD34 + CD38 -CD90 -CD45RA + phenotype (Fig. 6e) . Indeed, in contrast to patients with CP-CML (Supplementary Fig. 6 ), all patients with BC analyzed showed a marked expansion of Lin -CD34 + CD38 -CD90 -CD45RA + lymphoid-primed multipotent progenitor (LMPP)-like cells (Supplementary Fig. 15 ), a population previously implicated in the propagation of acute leukemia 38 . Finally, to explore a possible genetic basis for clonal evolution within the pre-BC SCs, we carried out exome sequencing of the patient with early lymphoid BC, which revealed a somatic RUNX1 mutation (c.G521A, Supplementary Fig. 16a ). To track acquisition of the RUNX1 mutation within the BCR-ABL + SC compartment, we carried out parallel targeted amplification of both BCR-ABL and the RUNX1 mutation. All four pre-BC cells falling in the CP-SC cluster were RUNX1 wild-type. By contrast, all RUNX1 mutated pre-BC SCs (n = 43) were found within the BC-SC cluster (P < 0.01). This distinct distribution of the RUNX1 mutation was confirmed by single-cell qPCR (Supplementary Fig. 16b,c) . Furthermore, differentially expressed genes between the pre-BC CP-SC and BC-SC clusters were typically RUNX1 target genes (Fig. 6f) . These findings are consistent with the acquisition of a RUNX1 mutation as a key genomic event occurring during pre-BC, which drives subsequent BC transformation-at least in this one patient-with an expansion of lympho-myeloid transcriptionally primed LMPP-like SCs preceding the clinical BC. This is also consistent with our observed expansion of this distinct SC population in both patients with myeloid and lymphoid BC (Supplementary Fig. 15 ). These data illustrate how integrated single-cell gene expression, mutational profiling and index sorting can be used to unravel CSC heterogeneity and reveal insights that may help to predict and understand subsequent disease progression.
DISCUSSION
Single-cell gene-expression approaches offer great promise to explore the cellular heterogeneity that might underlie therapy resistance and disease progression in cancer [1] [2] [3] 8, 10, 11, 16, 17 , none the least in rare CSC populations. This is of crucial importance, given that therapeutic elimination of all CSCs is not only required but might also be sufficient to cure cancers 3 . However, a lack of coverage in the RNA-sequencing data has precluded parallel mutation analysis 10, 11 , representing a major limitation with current techniques.
We used CML as the disease model for single-cell CSC analysis because the identity of the CSC compartment is well established 39 , and the persistence of rare CML-SCs during therapy remains a key challenge 16 . Although certain cell-surface markers have been proposed to allow for selective enrichment of CML-SCs 40-42 , they are not reproducible across all patients, nor do they allow for effective purification of BCR-ABL + CML-SCs during remission. In reality, the presence of BCR-ABL remains the only unequivocal marker of CML-SC. Therefore, we herein established a method for single-cell RNA sequencing with markedly improved sensitivity for BCR-ABL detection as compared to standard techniques. This new technique uniquely allowed us to selectively analyze aberrant gene expression in BCR-ABL − SCs at diagnosis, which is of relevance in view of recent findings that cell-extrinsic factors disrupt normal stem/progenitor cells in CML mouse models and other hematological malignancies [21] [22] [23] . Our analysis revealed marked dysregulation of the TGF-β and TNF-α pathways in BCR-ABL − (as well as BCR-ABL + ) SCs, associated with increased SC quiescence. Moreover, we uncovered heterogeneity of BCR-ABL − SCs in patients with CML, with a distinct cluster of BCR-ABL − SCs already dominant at diagnosis in patients who later failed to achieve MMR on TKI treatment. Indeed, elevated serum levels of TNF-α and TGF-α also correlate with poor treatment response in CML 43 . Further validation studies in larger patient cohorts will be required to determine whether gene expression signatures of BCR-ABL − SCs might have utility as a clinically predictive biomarker. Targeting inflammatory pathways such as TGF-β and TNF-α might also be of therapeutic value, by reducing microenvironment-induced quiescence of CML-SCs, although further preclinical evidence of the feasibility of such an approach is needed before this could be taken forward into a clinical trial setting.
Our single-cell method also provided a unique opportunity to assess rare BCR-ABL + SCs persisting during TKI-induced remission 16, 17 . It was not possible to analyze resistant CML-SCs in patients who had already achieved deep molecular remissions owing to the very low frequency of BCR-ABL + SCs in these patients. However, analysis of samples from patients established on TKI, including serial samples and patients on long-term TKI (>1 year), identified a distinct subpopulation of highly quiescent BCR-ABL + SCs, already present at diagnosis, that is markedly selected for during otherwise clinically effective TKI treatment. Quiescence is a hallmark of many normal SCs, including HSCs, that confers selective resistance to therapeutic targeting 44, 45 . Crucially, our data, acquired using a whole-transcriptome approach, support that TKI-resistant CML-SCs are transcriptionally distinct from quiescent normal HSCs, with dysregulation of specific genes and pathways (TGF-β, TNF-α, JAK-STAT, CTNNB1 and NFKB1A) that might be selectively targeted in CML-SCs. Another recent study applied a single-cell targeted gene expression analysis of BCR-ABL + CML-SCs 46 , rather than unbiased single-cell global RNA sequencing. Although the much more restricted gene expression analysis focused on the heterogeneity of lineage programs in BCR-ABL + stem cells and improved strategies for prospective purification of CML-SCs, the findings in those studies also supported a TKI-induced enrichment of quiescent BCR-ABL + stem cells, albeit investigated following shortterm TKI treatment only.
CML is an ideal tractable disease model to which to apply this single-cell technique because of its relative genomic simplicity 15 . However, a number of our findings might also be more generally applicable to other malignant disease. For example, although limited by the relatively small numbers of BC patient samples available, our analysis of patients with BC-CML supports the idea that a single-cell approach may prove powerful for predicting imminent disease progression in CSC populations. Specifically, our ability to detect RUNX1 mutations in distinct BC CML-SCs subclones shows how a single-cell approach can help to unravel the mechanisms underlying clonal progression associated with certain mutations at the CSC level. However, further work is required to determine the feasibility of applying this new method to the detection of a range of other mutations and a number of possible limitations in the approach need to be considered. Some tumors are characterized by exceedingly complex clonal heterogeneity. It is likely that there will be a limitation in relation to the number of mutations that could be detected simultaneously by targeted amplification in individual cells before this affects the complexity of the RNA-seq library generated, although this remains to be determined. Our technique also relies on the transcriptional expression of the mutation of interest, and given the increasing level of interest in mutations in the noncoding space 47 , further modifications to this approach will be required, for example, to enable parallel genomic DNA analysis. Furthermore, to obtain a high level of sensitivity for BCR-ABL detection, the amplicon size used in this study was short and did not encompass the kinase domain of ABL. Longer BCR-ABL amplicons were less efficient at BCR-ABL detection (data not shown). We were therefore unable to detect the presence of kinase-domain mutations in individual cells, which are of relevance for TKI resistance 48 . Further modification to our technique will be required to detect multiple, distantly located mutations occurring within the same allele.
In summary, we present a novel method that allows for simultaneous single-cell RNA sequencing and high-sensitivity, targeted mutation detection. We demonstrate how this technique can be applied to unravel heterogeneity in clonal CSCs, as well as in coexisting and frequently suppressed normal SCs, to provide insights into cellular and molecular mechanisms of therapy resistance and clonal evolution. In principle, this approach could be applied across a broad range of clonal disorders. Although considerable technical challenges remain in relation to the standardization of single-cell genomics techniques, we anticipate that the next few years will see major inroads toward clinical application of this powerful new technology.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Cryopreserved BM mononuclear cells (MNCs) were thawed and processed for flow cytometry analysis, as previously described 4 .
FACS staining and single-cell sorting. All FACS experiments included singlecolor-stained CompBeads (BD Biosciences) and fluorescence-minus-one (FMO) controls. Live cells were selected on the basis of their nonpermeability and subsequent lack of fluorescence associated with 7AAD or DAPI. The combination of monoclonal antibodies used to identify hematopoietic stem and progenitor cell populations was previously described 4 and is shown in Supplementary  Table 12 . The cocktail of lineage markers used (Lin) was: CD2, CD3, CD4, CD7, CD8a, CD10, CD11b, CD14, CD19, CD20, CD56 and CD235ab. Single cells were isolated from BM samples of healthy controls or patients with CML. Single cells were FACS-sorted as Lin -CD34 + CD38 -. For some experiments, index-sort data of the mean fluorescence intensities (MFI) of CD90, CD45Ra and CD123 were also recorded for each individual cell isolated.
Single-cell sorting was performed on FACS ARIA II, FACS ARIA III or FACS ARIA Fusion (Becton Dickinson) directly into 96-well plates (PCR microplate Thermo-Fast 96 well, semi-skirted). To check the correct alignment of the sorter, BD FACS Accudrop Beads (BD Biosciences) were deposited initially onto the lid or film cover of a setup plate. After this sort, 50 beads were sorted into several wells of a clean PCR plate where it was checked that the beads formed a discrete drop in the center of the bottom of the well. If any splashing was noticed on the sides of the well, the alignment was adjusted. Single 488-Flow-Check Fluorospheres (Beckman Coulter) were then deposited into each well of a flat-bottomed, 96-well tissue-culture plate, and single-cell mode sorting was verified by checking the presence of 1 fluorosphere/well using a conventional fluorescence microscope. The investigators were not blinded when performing this and following steps of the experiments. Experiments were not randomized.
Short-term culture from single cells for first division measurement. Single Lin -CD34 + CD38 -cells from normal BM donors or from patients with CML were sorted using FACSAriaIII into 60-well Terasaki plates containing 25 µl of Stemspan SFEM (Stemcell Technologies) medium supplemented with 10% BIT 9500 serum substitute (Stemcell Technologies), 2-mM l-glutamine (P A A Laboratories), 10-4 M 2-mercaptoethanol (Sigma-Aldrich), 100 U/ml penicillin/ streptomycin (PAA), 100 ng/ml rhSCF (Amgen), 100 ng/ml rhFLT3-ligand (FL; Immunex), 50 ng/ml rhTPO (Peprotech), 10 ng/ml rhIL-3 (Peprotech), 10 ng/ml rhG-CSF (Amgen), 10 ng/ml rhIL-6 (Peprotech). rhTNF-α (Miltenyi Biotec) or rhTGF-β (Miltenyi Biotec) were added to the culture at 20 ng/ml, as indicated. Single cells were scored microscopically for number of cells that had reached time of first division after 96 h of culture.
Fluorescence in situ hybridization (FISH). For interphase FISH, Lin -CD34 + CD38 -cells were cytocentrifuged onto slides and hybridized with the LSI BCR/ABL Dual Color, Dual Fusion Translocation Probe (Abbot Molecular) spanning the ABL1 and BCR respective breakpoints involved in the t(9:22) translocation (ABL1: 9q34, BCR: 22q11.2). Fluorescence images were obtained with the use of fluorescence microscopy. In nuclei from normal cells lacking the t(9:22) translocation, the probe hybridizing to the ABL1 region appears as two orange signals, whereas the probe hybridizing to the BCR region appears as two green signals. Nuclei containing a balanced t(9;22) will display one orange and one green signal from the normal chromosomes 9 and 22 and two orange/green (yellow) fusion signals, one each from the derivative chromosomes 9 and 22.
Generation of single-cell cDNA libraries using Smart-seq2 protocol. Single K562 or Lin -CD34 + CD38 -cells were FACS-sorted into 96-well plates (Thermo) containing 4 µl of a lysis mix, including oligo dT (Biomers), RNAse inhibitor (Takara) and dNTPs mix (Fermentas), at concentrations described in the original Smart-seq2 protocol and listed in Supplementary Table 13 24 . ERCC spikes (AMbion) were pre-diluted to 1:400,000 from stock concentration and added to the lysis mix at a final dilution of 1:40,000,000. ERCC spikes were not included in the analysis of patient samples, given that a number of samples were analyzed before ERCC spikes were routinely included in the reaction. Retrotranscription and PCR amplification steps were performed following the Smart-seq2 protocol using reagent concentrations optimized for small cells (Supplementary Table 13 ). The thermal conditions for RT and PCR reactions were according to the original Smart-seq2 protocol. The number of cycles used for PCR amplification was 22. After PCR amplification, cDNA libraries from single cells were purified using Ampure XP magnetic beads according to the manufacturer's instructions, in a ratio of 0.8 to 1 with cDNA. After purification, the libraries were resuspended in 17.5 µl of buffer EB (Qiagen) and stored at -20 °C. Quality and concentration of the cDNA libraries generated was assessed using HighSensitivity Bioanalyzer (Agilent).
Generation of single-cell cDNA libraries using BCR-ABL tSS2 protocol. BCR-ABL targeted amplification Smart-seq2 protocol (tSS2) was implemented during both RT and PCR steps of Smart-seq2, as described in Supplementary Figure 2 . During RT and PCR amplification, a pair of primers recognizing the BCR and the ABL portion of the fusion transcripts (sequences indicated in Supplementary  Fig. 2b ) were added to the RT and PCR mixes, respectively, at the concentrations indicated in Supplementary Figure 2c in condition 6. The primers pair was designed to give rise to a PCR amplicon of 505 bp for BCR-ABL e14a2 transcript and 430 for BCR-ABL e13a2 transcript (Supplementary Table 13 ).
Generation of single-cell cDNA libraries using BCR-ABL targeted amplification protocol with C1 microfluidic platform. K562 cells were captured on a large-sized (17-to 25-µm cell diameter) C 1 Single-Cell Auto Prep IFC for mRNA sequencing (Fluidigm) using the Fluidigm C1 system. Cells were loaded onto the chip at a concentration of ~250k cells/ml and imaged by phase-contrast microscopy to check single-cell per capture site. Cells were lysed and cDNA prepared on the C1 Fluidigm chip, according to the manufacturer's protocol, using SMARTer Ultra Low RNA kit for Illumina (Clontech). BCR-ABL targeted amplification in the C1 setting was performed using the modified C1 PCR MIX protocol described in Supplementary Table 14 . BCR-ABL Taqman assay (20X) was included in the C1 PCR MIX at a final dilution of 1:495. Any other step in the C1 protocol was performed following manufacturer's indications.
Illumina library preparation and sequencing. 1.25 µl of cDNA was used for tagmentation reaction carried out with Nextera XT DNA Sample Preparation kit (Illumina) according to the manufacturer's instructions, but using one-fourth of the volumes. Purification of the product was done with a 1:1 ratio of AMPure XP beads, with a final elution in 17.5 µl in resuspension buffer provided from the Nextera kit. Samples were loaded on a High-Sensitivity DNA chip (Agilent Technologies) to check the size and quality of the indexed library, and the concentration was measured with Qubit High-Sensitivity DNA kit (Invitrogen). BCR-ABL + or BCR-ABL − SCs eligible for sequencing were selected on the basis of the quality of their indexed cDNA libraries (size 400-900 bp; concentration >4 ng/ml). The number of BCR-ABL + or BCR-ABL − SCs to be sequenced per patient was determined by availability of SCs from each sample and space available per flow cell to ensure sufficient depth of sequencing. Libraries were pooled to a final concentration ranging between 3 nM and 10 nM and were sequenced with Illumina HiSeq 2000 and Illumina Hiseq 4000 (51 bp single-end read) at the Wellcome Trust Centre for Human Genetics in Oxford.
BCR-ABL genotyping of single-cell cDNA libraries. BCR-ABL genotyping of cDNA libraries from single cells was performed using a qPCR reaction in a 384-well plate (Roche, Lightcycler). qPCR was performed in duplicate using 1.5 µl of the cDNA library for each reaction. The expression levels of BCR-ABL and GAPDH were measured using the following Taqman FAM-MGB assays BCR-ABL: Hs03024541_ft and GAPDH: Hs02758991_g1 (Life Technologies).
The reactions were performed using a minimum of 60 cycles of amplification. We used qPCR and not raw sequencing reads to genotype cells for presence of BCR-ABL owing to the low coverage of BCR-ABL in the sequencing data.
Exome sequencing. Genomic DNA was extracted from unfractionated BM MNCs from patient OX1931 at both pre-BC and BC stages using QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer's instructions. Exome capture was performed from GATC Biotech, using INVIEW Human Exome Library preparation Enrichment with SureSelectXT Human All Exon Kit for Illumina Paired-End Sequencing (Read length: 2 × 125 bp). The number of PCR cycles performed for the amplification of the adaptor-ligated library was five. The number of cycles used for the posthybridization captured library amplification step was 12. The enriched exome fragments were pooled and paired-end sequenced on a HiSeq 2000 platform (Illumina). From this, we obtained >60× on target coverage for the majority of positions for each of the samples.
Assessment of BCR-ABL tSS2 sensitivity using plasmid spike-in. BCR-ABL breakpoint region (e14a2) was PCR-amplified from cDNA of K562 cells using specific BCR-ABL primer set #1 described in Supplementary Figure 2b . The resulting PCR amplicon was Sanger sequenced before being cloned into the pcr-Blunt II-TOPO vector using Zero Blunt TOPO PCR Cloning Kit (Thermo Fisher). Correct size of the BCR-ABL insert was verified by PCR. Concentration of the resulting BCR-ABL plasmid was measured using Qubit (Invitrogen), and the absolute number of plasmid copies/µl was calculated. Several plasmid predilutions were produced to be able to spike in the retro-transcription reaction of single BCR-ABL − SCs (HSCs from a normal donor), the desired amount of plasmid copies (1, 2, 5,10, 20, 50, 100 and 1,000) always at a volume of 1 µl. The PCR step was performed according to the standard BCR-ABL tSS2 protocol. Quantification of the absolute number of BCR-ABL amplified copies after BCR-ABL tSS2 reaction was carried out by qPCR (Roche, Lightcycler) using a commercial BCR-ABL standard curve as a reference (Ipsogen BCR-ABL1 Mbcr, Qiagen). Analysis of quantitative PCR single-cell gene expression data. We calculated ∆Ct values, which are relative to the mean expression level of two housekeeping genes (B2M and GAPDH). As previously described 25, 50 , Ct values were subtracted from the limit of detection (CT = 30) followed by subtraction of the mean Ct value of housekeeping genes for each cell. Ct = 40 was used for the comparative analysis of the detection of BCR-ABL and GAPDH in K562 cells between Smart-seq2 and BCR-ABL tSS2 protocols. Cells not expressing at the 15th percentile of all genes, or of two housekeeping genes, were removed from the analysis. Analysis of differential gene expression between BCR-ABL + and BCR-ABL − SCs was performed using the Wilcoxon test and Fisher's exact test to compare expression level and expression frequency, respectively.
Analysis of single-cell RNA sequencing. Short reads (51 bp) were aligned to the human genome (GRCh37 assembly (hg19)) using Tophat 51 with a supplied set of known RefSeq transcripts as the input. The mapping parameters '-g 1' was used to allow one alignment to the reference for a given read. Expression values were quantified as read per kilobase of transcript length per million mapped reads (RPKM) on the basis of the RefSeq gene model using the rpkmforgenes 52 . As previously demonstrated, single-cell analyses reliably identified distinct subpopulations of cells at a sequencing depth of 50,000 reads per cell 53, 54 , we used cells with higher than 50,000 mapping reads and 1,000 detected genes (RPKM ≥1) for the downstream analysis. We used the genes that were highly expressed in more than 50% of each population of cells to identify the candidate outliers on the basis of gene expression level, similar to the method previously described in Singular from Fluidigm, using the standard method for the outlier detection 55 . The modified Z-scores were calculated using the formula 0.6745(xi -×)/MAD; MAD denoting the median absolute deviation and x denoting the median. Cells with an absolute modified Z-score of greater than 3 were considered to be candidate outliers (28 out of 2,287 cells), and these cells were monitored during the analysis. We found that excluding or including them in our analysis did not have any notable impact on the results.
Analysis of the effective sequencing depth. To examine the effective sequencing depth, we selected 12 normal HSCs with a sequencing depth larger than 6 million mapped reads. We randomly sampled reads in the range of 0.1 million to 6 million mapped reads and calculated a number of detected genes with RPKM ≥1 in each category. We observed that the detected number of genes plateaued at a sequencing depth of beyond 1 million mapped reads per cell (Fig. 2a) .
T-distributed stochastic neighbor embedding (tSNE) analysis. As previously described, the advantage of using tSNE over a traditional principal-component analysis is to visualize the projection of high-dimensional single-cell gene expression data into a low-dimensional space 25, 56, 57 . We selected genes expressed in ≥10 cells with a coefficient of variation score (CV), "standard deviation/mean, " ≥1 and the sum of expression values per gene of all analyzed cells in log 2 scale ≥1 for the tSNE analysis. We normalized the RPKM values into log 2 (RPKM) scale and set up the limit of detection at 1 RPKM. Log 2 scale of genes expressed at <1 RPKM was set to 0. Possible batches from processing samples in different dates were removed from expression values using the function "removeBatchEffect" in Limma package 58 . We then downloaded the tSNE software from https://lvdmaaten.github.io/tsne/ to perform the analysis, using the Matlab implementation with "initial dims=20" and "perplexity=20" parameters.
To identify highly variable genes, similarly to a previously described approach 56 , we fitted a simple noise model using the lowess model of mean expression level and the coefficient of variation (CV) to estimate the variable genes from each type of cells. The lowess model predicted 3,368, 5,611, and 5,011 and 5,522 genes from K562, BCR-ABL − and BCR-ABL + SCs (from diagnosis), and normal HSCs, respectively, that show high variation as compared to the whole genes set with mean of expression log 2 (RPKM) higher than 0. We next used these genes for the tSNE analysis, and compared the tSNE results to the previous tSNE results of different gene sets. We found the same pattern of clustering, suggesting reproducibility of our results. We then selected 3,368, 7,428 (combined variable genes from K562 and normal HSCs) and 8,589 (combined variable genes from BCR-ABL − SCs, BCR-ABL + SCs and normal HSCs) genes to generate Figures 1d, 2b and 3c , respectively. 5,011 and 5,611 variable genes in BCR-ABL + and BCR-ABL -SCs were used to generate Figure 4a ,b for the good-and poor-responder classifications.
For tSNE analysis of samples following TKI therapy, we performed the random-forests analysis of normal HSCs, BCR-ABL + SCs (diagnosis) and BCR-ABL + SCs (remission) cells using the "randomForest" package in R (ntree parameter = 2,000). We obtained the top-500 important genes, as measured by the Gini index (Supplementary Table 7 ). These genes were used to distinguish normal HSCs from BCR-ABL + SCs at diagnosis and during remission. We next used this gene set for tSNE analysis of the remission cells (Fig. 5a) . We applied K-means clustering (k = 3) on the basis of tSNE analysis results (from dimensions 1 and 2) to assign remission cells to group A and group B (Fig. 5a) .
For tSNE analysis of normal HSCs and K562 and BCR-ABL + SCs from diagnosis, pre-BC and BC samples, we obtained combined differentially expressed genes from the multiple-ways comparison. 207 genes shown to be differentially expressed between BCR-ABL + SCs from 18 patients with chronic-phase CML (n = 477), BCR-ABL + SCs at BC (n = 148), BCR-ABL + SCs at pre-BC (n = 185) and normal HSCs (n = 232). We next used this gene set for the tSNE to generate
